|
Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE). |
|
|
Employment - Warwickshire Head and Neck Clinic |
Leadership - Warwickshire Head and Neck Clinic; Warwickshire Head and Neck Clinic (I) |
Stock and Other Ownership Interests - Warwickshire Head and Neck Clinic |
|
Speakers' Bureau - Merck; MSD; Sanofi Pasteur |
Research Funding - AstraZeneca; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); Sanofi Pasteur (Inst); Silence Therapeutics (Inst) |
Travel, Accommodations, Expenses - Merck; MSD; Sanofi Pasteur |
|
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Honoraria - Glycotope GmbH |
Consulting or Advisory Role - Glycotope GmbH |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Puma Biotechnology |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Merck; Novartis; Pfizer |
Travel, Accommodations, Expenses - Lilly; Merck; MSD; Pfizer; Roche |